JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

4.54 -1.3

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.5

Максимум

4.55

Ключови измерители
By Trading Economics
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	15M 35M
Предишно отваряне	5.84
Предишно затваряне	4.54

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.02.2026 г., 23:57 ч. UTC

Пазарно говорене

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8.02.2026 г., 23:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.02.2026 г., 23:34 ч. UTC

Пазарно говорене

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8.02.2026 г., 23:26 ч. UTC

Пазарно говорене

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8.02.2026 г., 21:43 ч. UTC

Пазарно говорене

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8.02.2026 г., 21:16 ч. UTC

Пазарно говорене

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8.02.2026 г., 21:15 ч. UTC

Пазарно говорене

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.02.2026 г., 02:46 ч. UTC

Придобивния, сливания и поглъщания

Big Money, High Anxiety -- Barrons.com

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.02.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6.02.2026 г., 21:22 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Accelerating in January -- Market Talk

6.02.2026 г., 21:17 ч. UTC

Печалби

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6.02.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.02.2026 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6.02.2026 г., 21:13 ч. UTC

Печалби

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6.02.2026 г., 21:13 ч. UTC

Печалби

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6.02.2026 г., 21:04 ч. UTC

Пазарно говорене

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6.02.2026 г., 20:34 ч. UTC

Печалби

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.